Aging-Related Gene Signatures Point to Senescence in ME/CFS
In ME/CFS, the biology often looks diffuse at the bedside and remarkably specific at the transcriptome. A PLOS One analysis tracked that specificity through an aging-focused gene screen and converged on two genes—SGK1 and HMGCR—as candidate markers tied to cellular senescence and immune dysregulation.
The study design moved in layers rather than in a single sweep. Investigators first mapped differentially expressed genes between control and ME/CFS samples, then intersected those genes with an aging-related gene set and modules derived from weighted gene co-expression network analysis. The overlap narrowed the field to seven candidate genes, a relatively small number that makes the eventual focus on SGK1 and HMGCR more clinically legible. In a disorder as heterogeneous as ME/CFS, narrowing signal from background is not cosmetic; it is the entire challenge.
From Broad Differential Expression to a Narrower Molecular Signal
The early expression analysis showed clear separation between control and ME/CFS samples, with both up-regulated and down-regulated transcripts contributing to the phenotype. A volcano plot and heatmap defined the molecular differences, while WGCNA was used to organize genes into co-expression modules and relate them to disease status. The resulting module-trait relationship strengthened the case that the observed differences were not random noise but part of a structured biological program.
A second filter came from candidate selection methods used to prioritize hub genes. Lasso regression and random forest modeling both converged on SGK1 and HMGCR, giving the pair a stronger analytic foothold than the full seven-gene set. External evaluation in an independent peripheral blood mononuclear cell RNA-seq cohort supported the same direction of expression change, which is important because one dataset alone can exaggerate a signature that vanishes elsewhere.
The pathway analysis needs a careful reading. Exploratory KEGG enrichment suggested several routes of interest, but those pathways did not remain statistically significant after multiple-testing correction. In practice, that means the pathway signals may still be biologically suggestive, but they cannot carry the same evidentiary weight as the gene-level findings. The stronger signal here sits with senescence-linked transcription and the two prioritized genes.
Senescence Pathways Cluster Around SGK1 and HMGCR
Single-gene stratified gene set enrichment analysis linked both hubs to cellular senescence, and the downstream pathway patterns offer a plausible mechanistic frame. HMGCR aligned with VEGF signaling, neutrophil NETs, cell cycle activity, and steroid biosynthesis. SGK1 aligned with FcγR-mediated phagocytosis, autophagy, lysosome biology, and apoptosis. Those pathways are not interchangeable. They sketch two overlapping but distinct biological routes into the same clinical territory: chronic immune activation, altered cell survival, and impaired resolution of cellular stress.
A transcript that links to senescence in immune cells is not a decorative biomarker. Senescent cells change cytokine output, distort tissue repair, and can sustain inflammatory signaling long after the initial insult has faded. In ME/CFS, where patients often describe persistent exhaustion, post-exertional worsening, and neuroimmune symptoms that resist easy categorization, a senescence signature offers a coherent explanation for chronicity without implying a single cause.
Single-Cell Data Place SGK1 in Monocytes and Neutrophils
Single-cell transcriptomics sharpened the picture further. Integrated analysis of 12 representative samples combined ME/CFS and healthy controls with aging samples, allowing the investigators to examine where SGK1 sits at the cellular level. SGK1 expression appeared predominantly in monocyte and neutrophil clusters in ME/CFS-associated samples. That localization matters because those cells sit at the intersection of innate immunity, inflammatory signaling, and rapid stress responses.
The distribution also fits the pathway findings. Monocytes and neutrophils are central to phagocytosis, autophagy, lysosomal function, and NET formation. If SGK1 is elevated in those compartments, it may reflect a state in which innate immune cells are locked into a maladaptive activation pattern rather than a transient response to infection or injury. The expression map therefore gives the bulk RNA signal a cellular address.
One experimental figure makes the point sharply. In a β-gal-induced senescence model, mRNA levels of P16, P53, P21, and SGK1 rose significantly. After SGK1 knockdown, P21, P53, and P16 fell. The directionality is notable because it places SGK1 upstream of core senescence markers rather than merely adjacent to them. In cell biology terms, the gene is not only present in the neighborhood; it appears to participate in the circuitry.
HMGCR and SGK1 May Reflect Different Arms of the Same Disorder
HMGCR and SGK1 may represent two biologically distinct but converging components of ME/CFS. HMGCR points toward cholesterol and steroid biosynthesis, VEGF signaling, and neutrophil extracellular trap biology, all of which can influence vascular tone, membrane dynamics, and inflammatory persistence. SGK1 points more directly toward autophagy, apoptosis, and phagocytic processing. Together, they suggest a disorder that may involve aberrant immune-cell metabolism, prolonged stress signaling, and impaired cleanup of damaged cellular material.
The bedside implication is not that these markers are ready for routine testing. It is that ME/CFS may be more amenable to mechanistic stratification than symptom checklists alone suggest. If aging-related pathways truly sit inside the disease process, then the usual frame of fatigue as a nonspecific endpoint becomes too small. The molecular pattern points to stress biology, immune aging, and senescence-related remodeling as candidates for deeper therapeutic exploration.
What the Data Support, and What They Do Not Yet Prove
The dataset supports a focused transcriptomic association, not a definitive causal map. The study used public datasets, bioinformatic prioritization, external validation in an independent cohort, and a small experimental knockdown component, but it did not establish whether SGK1 and HMGCR drive ME/CFS, compensate for it, or simply mark its immunologic footprint. The KEGG findings also require restraint because nominal pathway signals did not survive multiple-testing correction.
Still, the most defensible conclusion is stronger than a generic biomarker hunt. Aging-related differential expression, senescence enrichment, and cell-specific SGK1 localization all point in the same direction. ME/CFS may carry a measurable senescence-associated immune signature, and SGK1, with HMGCR close behind, could become useful entry points for future validation in larger, clinically annotated cohorts.